JP2019510519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510519A5 JP2019510519A5 JP2019503776A JP2019503776A JP2019510519A5 JP 2019510519 A5 JP2019510519 A5 JP 2019510519A5 JP 2019503776 A JP2019503776 A JP 2019503776A JP 2019503776 A JP2019503776 A JP 2019503776A JP 2019510519 A5 JP2019510519 A5 JP 2019510519A5
- Authority
- JP
- Japan
- Prior art keywords
- bacteriophage
- optionally
- terminal
- region
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001515965 unidentified phage Species 0.000 claims 27
- 210000004899 c-terminal region Anatomy 0.000 claims 11
- 230000001580 bacterial effect Effects 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 210000004897 n-terminal region Anatomy 0.000 claims 9
- 108020003175 receptors Proteins 0.000 claims 9
- 102000005962 receptors Human genes 0.000 claims 9
- 101710166729 Tail fiber protein Proteins 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 241000894006 Bacteria Species 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000010261 cell growth Effects 0.000 claims 4
- 108700012359 toxins Proteins 0.000 claims 4
- 241000589516 Pseudomonas Species 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- 241000194107 Bacillus megaterium Species 0.000 claims 1
- 101100447530 Dictyostelium discoideum gpi gene Proteins 0.000 claims 1
- 208000001860 Eye Infections Diseases 0.000 claims 1
- 206010048685 Oral infection Diseases 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 101100120969 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) pgi1 gene Proteins 0.000 claims 1
- 101100455520 Streptomyces lasalocidi lsd19 gene Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 101150037483 bkdA gene Proteins 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000011323 eye infectious disease Diseases 0.000 claims 1
- -1 fda Proteins 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 101150078665 lasB gene Proteins 0.000 claims 1
- 230000002101 lytic effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 101150084945 pdhA gene Proteins 0.000 claims 1
- 101150053253 pgi gene Proteins 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000005067 remediation Methods 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 101150078369 rpsB gene Proteins 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022054747A JP2022084893A (ja) | 2016-04-08 | 2022-03-30 | 改変バクテリオファージ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1606319.0 | 2016-04-08 | ||
| GB201606319 | 2016-04-08 | ||
| PCT/EP2017/058470 WO2017174810A1 (en) | 2016-04-08 | 2017-04-07 | Modified bacteriophage |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022054747A Division JP2022084893A (ja) | 2016-04-08 | 2022-03-30 | 改変バクテリオファージ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510519A JP2019510519A (ja) | 2019-04-18 |
| JP2019510519A5 true JP2019510519A5 (https=) | 2020-05-07 |
| JP7051809B2 JP7051809B2 (ja) | 2022-04-11 |
Family
ID=58692459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503776A Active JP7051809B2 (ja) | 2016-04-08 | 2017-04-07 | 改変バクテリオファージ |
| JP2022054747A Pending JP2022084893A (ja) | 2016-04-08 | 2022-03-30 | 改変バクテリオファージ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022054747A Pending JP2022084893A (ja) | 2016-04-08 | 2022-03-30 | 改変バクテリオファージ |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11732243B2 (https=) |
| EP (2) | EP3901255A1 (https=) |
| JP (2) | JP7051809B2 (https=) |
| AU (2) | AU2017246593C1 (https=) |
| CA (1) | CA3020375A1 (https=) |
| DK (1) | DK3440200T3 (https=) |
| ES (1) | ES2867029T3 (https=) |
| HR (1) | HRP20210614T1 (https=) |
| HU (1) | HUE054475T2 (https=) |
| LT (1) | LT3440200T (https=) |
| PL (1) | PL3440200T3 (https=) |
| PT (1) | PT3440200T (https=) |
| SI (1) | SI3440200T1 (https=) |
| WO (1) | WO2017174810A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024259013A1 (en) * | 2023-06-13 | 2024-12-19 | Virginia Tech Intellectual Properties, Inc. | Engineered phages and uses thereof |
| WO2025143108A1 (ja) * | 2023-12-27 | 2025-07-03 | 株式会社Arrowsmith | 緑膿菌バクテリオファージ |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310191B1 (en) | 1998-02-02 | 2001-10-30 | Cosmix Molecular Biologicals Gmbh | Generation of diversity in combinatorial libraries |
| ATE239077T1 (de) | 1997-01-31 | 2003-05-15 | Cosmix Molecular Biolog Gmbh | Erzeugung von diversität in kombinatorischen banken |
| US6492161B1 (en) * | 1999-06-02 | 2002-12-10 | Prokaria Ltd. | Bacteriophage RM 378 of a thermophilic host organism |
| ES2252263T3 (es) | 2000-07-25 | 2006-05-16 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Bacteriofago que tiene una gama de hospedadores multiple. |
| GB0028130D0 (en) * | 2000-11-17 | 2001-01-03 | Phico Therapeutics Ltd | Polypeptide and uses thereof |
| EP1384779A1 (en) | 2002-07-26 | 2004-01-28 | Cosmix Molecular Biologicals GmbH | Method for generating molecules with specific properties by recombination and selection |
| GB0314469D0 (en) * | 2003-06-20 | 2003-07-23 | Phico Therapeutics Ltd | Antimicrobial compositions and uses thereof |
| ES2527994T3 (es) * | 2003-07-23 | 2015-02-03 | Biocontrol Limited | Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa |
| GB0715416D0 (en) | 2007-08-07 | 2007-09-19 | Phico Therapeutics Ltd | Modified bacteriophage |
| DE102010013834A1 (de) | 2008-03-30 | 2010-12-16 | VLB Berlin e. V. Institut für Mikrobiologie | Mittel zur Blockierung der Vermehrung und der Abtötung von Bakterien |
| WO2010141135A2 (en) | 2009-03-05 | 2010-12-09 | Trustees Of Boston University | Bacteriophages expressing antimicrobial peptides and uses thereof |
| WO2015035168A1 (en) * | 2013-09-05 | 2015-03-12 | Massachusetts Institute Of Technolgy | Tuning bacteriophage host range |
| GB201417805D0 (en) | 2014-10-08 | 2014-11-19 | Phico Therapeutics Ltd | Modifield bacteriophage |
| GB201417810D0 (en) * | 2014-10-08 | 2014-11-19 | Phico Therapeutics Ltd | Modifying bacteriophage |
| GB201417811D0 (en) * | 2014-10-08 | 2014-11-19 | Phico Therapeutics Ltd | Modifying bacteriophage |
| GB201417808D0 (en) * | 2014-10-08 | 2014-11-19 | Phico Therapeutics Ltd | Modified bacteriophage |
-
2017
- 2017-04-07 PT PT177223799T patent/PT3440200T/pt unknown
- 2017-04-07 JP JP2019503776A patent/JP7051809B2/ja active Active
- 2017-04-07 US US16/092,096 patent/US11732243B2/en active Active
- 2017-04-07 EP EP21158520.3A patent/EP3901255A1/en not_active Withdrawn
- 2017-04-07 SI SI201730732T patent/SI3440200T1/sl unknown
- 2017-04-07 LT LTEP17722379.9T patent/LT3440200T/lt unknown
- 2017-04-07 HU HUE17722379A patent/HUE054475T2/hu unknown
- 2017-04-07 HR HRP20210614TT patent/HRP20210614T1/hr unknown
- 2017-04-07 AU AU2017246593A patent/AU2017246593C1/en active Active
- 2017-04-07 EP EP17722379.9A patent/EP3440200B1/en active Active
- 2017-04-07 WO PCT/EP2017/058470 patent/WO2017174810A1/en not_active Ceased
- 2017-04-07 PL PL17722379T patent/PL3440200T3/pl unknown
- 2017-04-07 ES ES17722379T patent/ES2867029T3/es active Active
- 2017-04-07 CA CA3020375A patent/CA3020375A1/en active Pending
- 2017-04-07 DK DK17722379.9T patent/DK3440200T3/da active
-
2022
- 2022-03-30 JP JP2022054747A patent/JP2022084893A/ja active Pending
-
2023
- 2023-05-10 US US18/315,255 patent/US20230416694A1/en not_active Abandoned
- 2023-07-07 AU AU2023204409A patent/AU2023204409A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shuwen et al. | Intestinal phages interact with bacteria and are involved in human diseases | |
| Shahrooei et al. | Vaccination with SesC decreases Staphylococcus epidermidis biofilm formation | |
| Haddad Kashani et al. | Recombinant endolysins as potential therapeutics against antibiotic-resistant Staphylococcus aureus: current status of research and novel delivery strategies | |
| Saising et al. | Activity of gallidermin on Staphylococcus aureus and Staphylococcus epidermidis biofilms | |
| US11180744B2 (en) | Acinetobacter lysins | |
| Lloyd | Alternatives to conventional antimicrobial drugs: a review of future prospects | |
| CN102676490B (zh) | 一种金黄色葡萄球菌噬菌体溶壁酶及其制备方法和应用 | |
| Simoes et al. | Novel antibacterial agents: an emergent need to win the battle against infections | |
| Vaillancourt et al. | Suicin 3908, a new lantibiotic produced by a strain of Streptococcus suis serotype 2 isolated from a healthy carrier pig | |
| US12257284B2 (en) | Lantibiotics, lantibiotic-producing bacteria, compositions and methods of production and use thereof | |
| CN107073073B (zh) | 经肺施用绿脓菌素用于治疗细菌性呼吸道感染 | |
| Hwang et al. | Engineering microbes for targeted strikes against human pathogens | |
| Giau et al. | Recent advances in the treatment of C. difficile using biotherapeutic agents | |
| Heinzinger et al. | Evaluating the translational potential of bacteriocins as an alternative treatment for Staphylococcus aureus infections in animals and humans | |
| CN107022001A (zh) | 一种分离的母乳内源性抗菌多肽及其应用 | |
| JP2026031930A (ja) | クレブシエラの制御のためのクレビシン | |
| CN108026155B (zh) | 新抗微生物肽、它们的变体和用途 | |
| Alqahtani et al. | Recombinant R2-pyocin cream is effective in treating Pseudomonas aeruginosa-infected wounds | |
| JP2019510519A5 (https=) | ||
| Palaniappan et al. | Therapeutic efficacy of bacteriophages | |
| HRP20210614T1 (hr) | Modificirani bakteriofag | |
| Makobongo et al. | In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori | |
| CN107849103B (zh) | 新抗微生物肽、它们的变体和用途 | |
| CN106220737A (zh) | 融合蛋白及其在治疗艰难梭菌相关疾病中的应用 | |
| Yacoub et al. | Effect of Nk-lysin peptides on bacterial growth, MIC, antimicrobial resistance, and viral activities |